Topic: drug delivery technology
Impel’s championing of nasal delivery of drugs has been rewarded with new financing that will help it advance three drugs through the clinic.
Clearside Biomedical has cratered after revealing its top drug failed a phase 3 trial in retinal vein occlusion, a common cause of vision loss.
Royal Philips and Ypsomed plan to install digital, at-home adherence tracking across a line of connected injection and infusion systems.
Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.
Aerie Pharma—just months away from a possible approval for its lead glaucoma drug—is hoping to unlock the potential of a key pipeline compound with help from Netherlands company Royal DSM.
The past week saw scientific advances in drug delivery, bladder cancer and the genetic underpinnings of depression.
ViaCyte and W.L. Gore will develop a delivery device for cell therapies that will protect the cells from immune rejection.
Intec Pharma has again tapped the Michael J. Fox Foundation for Parkinson’s Research for development of its Parkinson’s med AP-CD/LD.